Targeting CCR1 Remodels the Tumor Microenvironment and Relieves Immunosuppression in Pancreatic Cancer

Investigators showed that targeting C-C motif chemokine receptor 1 (CCR1) remodels the pancreatic tumor microenvironment, reducing myeloid-driven immunosuppression and enhancing CD8+ T-cell activity and immunotherapy response.